The U.S. Food and Drug Administration (FDA) approved the first-ever epinephrine nasal spray, Neffy, for the emergency treatment of allergic reactions, including life-threatening anaphylaxis.
The new treatment, a needle-free alternative, could be used for managing severe allergic responses in children and adults, weighing at least 66 pounds, the FDA said in a news release.
